Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/62942
Title: The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function
Authors: Patchareeya Amput
Christian McSweeney
Siripong Palee
Arintaya Phrommintikul
Siriporn C. Chattipakorn
Nipon Chattipakorn
Keywords: Pharmacology, Toxicology and Pharmaceutics
Issue Date: 1-Jan-2019
Abstract: © 2018 Elsevier Masson SAS Low density lipoprotein cholesterol (LDL-C) is a well-established risk factor for cardiovascular disease. Although there are several developed lipid lowering drugs such as statins and fenofibrates, many patients do not achieve an adequate response. Recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been developed as a new therapeutic strategy for cholesterol regulation. PCSK9 binds to low density lipoprotein receptors (LDLR) and initiates LDLR degradation, elevating LDL-C. Therefore, PCSK9 inhibition could exert beneficial effects on cardiovascular disease outcomes. This review comprehensively summarizes and discusses the effects of PCSK9 inhibitors on lipid metabolism and cardiovascular function comparatively with current lipid lowering drugs. This review also details essential information regarding the cardiovascular benefits of PCSK9 inhibition which could encourage further clinical studies.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85056208509&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/62942
ISSN: 19506007
07533322
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.